The Latest Cardiac and Vascular News
– Phase 3 ELEVATE UC 52 and 12 on course for Q1 2022 topline data readout February 23, 2022 04:05 PM Eastern Standard Time PARK CITY, Utah–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results […]
– Significant pipeline progress with potentially first- or best-in-class drug candidates – Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the […]
– Phase 2b ADVISE trial evaluating etrasimod in atopic dermatitis (AD) enrollment complete, topline data expected Q4 2020 – Progressing first- or best-in-class drug candidates with liquidity position of ~$1.3bn as of June 30, 2020 SAN DIEGO, Aug. 5, 2020 /PRNewswire/ — Arena […]
SAN DIEGO, Jan. 24, 2019 /PRNewswire/ — Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced the closing of the global license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for the Arena-discovered, Phase 3 investigational drug candidate ralinepag, a next-generation, oral, selective and potent prostacyclin receptor agonist for […]
